{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:14:55Z","timestamp":1790817295698,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Behavioural and psychological symptoms of dementia (BPSD) are frequent in patients with severe dementia and represent a major clinical challenge. Cannabinoid-based medications (CBM) have been proposed as a possible therapeutic option, but clinical evidence is still limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a multicenter, randomised, double-blind, placebo-controlled crossover trial in five long-term care facilities in Geneva, Switzerland. Patients with severe dementia received oral \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD) oil (1:2 ratio, up to 20\u00a0mg\/40\u00a0mg daily) and placebo in two 8-week periods separated by a 1-week washout. The primary outcome was agitation measured by the Cohen\u2013Mansfield Agitation Inventory (CMAI). Secondary outcomes included behavioural scales, pain, as-needed psychotropic medication use and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-five patients (average age 83\u00a0years) were randomised, and nineteen completed both study periods. No significant difference was observed between active treatment and placebo for the CMAI and other main behavioural outcomes. However, the use of pro re nata psychotropic medications was significantly lower during the active treatment period. The treatment was well tolerated, and no serious adverse events related to the study drug were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-life crossover study, THC\/CBD oil did not show superiority over placebo in reducing agitation in severe dementia. However, it was safe and associated with a significant reduction in the use of as-needed psychotropic medications prescribed for behavioural and psychological symptoms of dementia. CBM may represent a possible adjunctive option in selected patients, but further studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ageing\/afag239","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:25:40Z","timestamp":1785151540000},"source":"Crossref","is-referenced-by-count":2,"title":["A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-2831","authenticated-orcid":false,"given":"Federica","family":"Bianchi","sequence":"first","affiliation":[{"name":"Palliative Medicine Division, Department of Rehabilitation and Geriatrics, Geneva University Hospitals , Geneva, GE ,","place":["Switzerland"]},{"name":"Fondation pour l\u2019accueil et l\u2019h\u00e9bergement de personnes \u00e2g\u00e9es , Geneva, GE ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Broers","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Geneva , Geneva, GE ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules Alexandre","family":"Desmeules","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, University of Geneva , Geneva, GE ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeline","family":"Langlois","sequence":"additional","affiliation":[{"name":"Fondation pour l\u2019accueil et l\u2019h\u00e9bergement de personnes \u00e2g\u00e9es , Geneva, GE ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wampfler","sequence":"additional","affiliation":[{"name":"Fondation pour l\u2019accueil et l\u2019h\u00e9bergement de personnes \u00e2g\u00e9es , Geneva, GE ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Curtin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, University of Geneva , Geneva, GE ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Pautex","sequence":"additional","affiliation":[{"name":"Palliative Medicine Division, Department of Rehabilitation and Geriatrics, Geneva University Hospitals , Geneva, GE ,","place":["Switzerland"]},{"name":"Faculty of Medicine, Department of Rehabilitation and Geriatrics, University of Geneva , Geneva, GE ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026081811250132700_ref1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-191092","article-title":"The prevalence of dementia: a systematic review and meta-analysis","volume":"73","author":"Cao","year":"2020","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2026081811250132700_ref2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40520-025-03021-8","article-title":"Aging, longevity, and healthy aging: the public health approach","volume":"37","author":"Gianfredi","year":"2025","journal-title":"Aging Clin Exp Res"},{"key":"2026081811250132700_ref3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jpainsymman.2020.04.027","article-title":"Redefining palliative care-a new consensus-based definition","volume":"60","author":"Radbruch","year":"2020","journal-title":"J Pain Symptom Manage"},{"key":"2026081811250132700_ref4","doi-asserted-by":"publisher","first-page":"e102218","DOI":"10.1002\/alz70858_102218","article-title":"Palliative care resource utilization in patients with prion disease","volume":"21","author":"Day","year":"2025","journal-title":"Alzheimer\u2019s Dementia"},{"key":"2026081811250132700_ref5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jamda.2024.03.007","article-title":"Guideline recommendations on behavioral and psychological symptoms of dementia: a systematic review","volume":"25","author":"Watt","year":"2024","journal-title":"J Am Med Dir Assoc"},{"key":"2026081811250132700_ref6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1055\/a-2262-7837","article-title":"Cannabinoids for behavioral symptoms in dementia: an overview","volume":"57","author":"Broers","year":"2024","journal-title":"Pharmacopsychiatry"},{"key":"2026081811250132700_ref7","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Brit J Clinical Pharma"},{"key":"2026081811250132700_ref8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/plants11101357","article-title":"A systematic review on cannabinoids for neuropathic pain administered by routes other than oral or inhalation","volume":"11","author":"Quintero","year":"2022","journal-title":"Plants"},{"key":"2026081811250132700_ref9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1089\/can.2022.0254","article-title":"Effectiveness and safety of cannabinoids as an add-on therapy in the treatment of resistant spasticity in multiple sclerosis: a systematic review","volume":"8","author":"Martinez-Paz","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"2026081811250132700_ref10","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.17117","article-title":"Therapeutic use of cannabis and cannabinoids: benefits and risks","author":"Zhai","year":"2025","journal-title":"Polish Arch Internal Med"},{"key":"2026081811250132700_ref11","volume-title":"Trends, Charts, Data"},{"key":"2026081811250132700_ref12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40290-022-00447-7","article-title":"The characteristics of clinical trials on Cannabis and cannabinoids: a review of trials for therapeutic or drug development purposes","volume":"36","author":"Modaresi","year":"2022","journal-title":"Pharm Med"},{"key":"2026081811250132700_ref13","doi-asserted-by":"publisher","first-page":"957665","DOI":"10.3389\/fnagi.2022.957665","article-title":"Cannabinoids for behavioral symptoms in severe dementia: safety and feasibility in a long-term pilot observational study in nineteen patients","volume":"14","author":"Pautex","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"2026081811250132700_ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1108832","article-title":"Medical cannabinoids for painful symptoms in patients with severe dementia: a randomized, double-blind cross-over placebo-controlled trial protocol","volume":"4","author":"Bianchi","year":"2023","journal-title":"Front Pain Res"},{"key":"2026081811250132700_ref15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1053\/SCNP00100325","article-title":"Agitation: subtypes and their mechanisms","volume":"1","author":"Cohen-Mansfield","year":"1996","journal-title":"Semin Clin Neuropsychiatry"},{"key":"2026081811250132700_ref16","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/wnl.44.12.2308","article-title":"The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"2026081811250132700_ref17","first-page":"191-194","article-title":"The Doloplus-2 scale\u2013evaluating pain in the elderly., pt 191-194","volume":"8","author":"Lefebvre-Chapiro","year":"2001","journal-title":"Eur J Palliat Care"},{"key":"2026081811250132700_ref18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.amjmed.2022.01.057","article-title":"The coronary artery risk development in young adults (CARDIA) study","volume":"135","author":"Jakob","year":"2022","journal-title":"Am J Med"},{"key":"2026081811250132700_ref19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3928\/00989134-20210610-02","article-title":"Cannabidiol (CBD) use by older adults for acute and chronic pain","volume":"47","author":"Porter","year":"2021","journal-title":"J Gerontol Nurs"},{"key":"2026081811250132700_ref20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/bcpt.12586","article-title":"Evaluation of mutual drug\u2013drug interaction within Geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method","volume":"119","author":"Bosilkovska","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026081811250132700_ref21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/sim.4780071010","article-title":"Cross-over trials, carry-over effects and the art of self-delusion","volume":"7","author":"Senn","year":"1988","journal-title":"Stat Med"},{"key":"2026081811250132700_ref22","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1098\/rstb.2010.0394","article-title":"Lessons learned from placebo groups in antidepressant trials","volume":"366","author":"Mora","year":"2011","journal-title":"Philos Trans R Soc B"},{"key":"2026081811250132700_ref23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026081811250132700_ref24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/applbiosci2040042","article-title":"Statistical analysis of ceiling and floor effects in medical trials","volume":"2","author":"Arslan","year":"2023","journal-title":"Appl Biosci"},{"key":"2026081811250132700_ref25","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70219","article-title":"Clinical study to evaluate drug interactions of cannabidiol with citalopram and morphine in healthy adults","author":"Salcedo","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"2026081811250132700_ref26","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70415","article-title":"Low-dose cannabidiol increases plasma concentrations of amitriptyline: a clinical drug-drug interaction study","author":"Gorbenko","year":"2025","journal-title":"Br J Clin Pharmacol"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/55\/8\/afag239\/70685447\/afag239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/55\/8\/afag239\/70685447\/afag239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:26:01Z","timestamp":1787066761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afag239\/8763877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afag239","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"afag239"}}